Interaction between midazolam and clarithromycin in the elderly.

Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.90

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol (2015) 0.87

Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clin Pharmacol Ther (2011) 0.83

Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies. Eur J Clin Pharmacol (2012) 0.82

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams. Pharmaceutics (2011) 0.76

Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol (2008) 0.75

[Drug interactions in geriatric medicine]. Wien Med Wochenschr (2009) 0.75

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther (1994) 5.22

The human intestinal cytochrome P450 "pie". Drug Metab Dispos (2006) 2.31

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24

Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology (1984) 2.14

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85

The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther (1998) 1.72

Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm (2005) 1.54

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther (1994) 1.36

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother (1992) 1.33

Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol (1993) 1.31

Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol (1992) 1.31

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol (1994) 1.26

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther (1994) 1.22

Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol (1997) 1.19

CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos (2005) 1.19

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther (2006) 1.11

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc (2005) 1.09

The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther (1999) 1.08

The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol (1997) 1.08

Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother (1992) 1.03

The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation (1994) 1.03

Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol (1992) 1.02

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99

Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock. Ann Pharmacother (2005) 0.95

The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation (2001) 0.94

Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther (1998) 0.89

Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev (1992) 0.88

Absorption, distribution and elimination of felodipine in man. Drugs (1985) 0.88

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther (1998) 0.85

Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther (1997) 0.83

The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther (2000) 0.83

[Clinical pharmacology of midazolam]. Anaesthesiol Reanim (1989) 0.77

Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant (1994) 0.77

Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71

Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27

Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol (2007) 2.88

MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol (2008) 2.45

The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators. Nat Struct Biol (2003) 2.29

Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89

Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J (2005) 1.71

High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation (2004) 1.68

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65

Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology (2008) 1.63

Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58

Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52

Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51

Sequence-specific recognition of RNA hairpins by the SAM domain of Vts1p. Nat Struct Mol Biol (2006) 1.45

The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44

Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog (2013) 1.43

Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41

Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq. RNA (2010) 1.39

Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38

GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage (2005) 1.35

Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27

Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos (2006) 1.26

MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J Virol (2010) 1.23

Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23

Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.18

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13

Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest (2006) 1.13

Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11

Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11

The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10

Choosing SNPs using feature selection. Proc IEEE Comput Syst Bioinform Conf (2005) 1.09

Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med (2007) 1.08

Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun (2010) 1.07

Association between the CYP3A5 genotype and blood pressure. Hypertension (2004) 1.07

Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06

Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-Seq. J Virol (2011) 1.06

Confidentiality in genome research. Science (2006) 1.06

Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther (2007) 1.04

Sustained neuronal activity generated by glial plasticity. J Neurosci (2011) 1.03

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther (2006) 1.02

The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos (2002) 1.01

Autologous tenocyte therapy for experimental Achilles tendinopathy in a rabbit model. Tissue Eng Part A (2011) 1.00

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos (2009) 0.99

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS (2008) 0.99

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99

Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99

Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos (2011) 0.97

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos (2004) 0.96

Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96

Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol (2006) 0.95

Epstein-Barr virus and human herpesvirus 6 detection in a non-Hodgkin's diffuse large B-cell lymphoma cohort by using RNA sequencing. J Virol (2013) 0.95

Differentiation of rodent bone marrow mesenchymal stem cells into intervertebral disc-like cells following coculture with rat disc tissue. Tissue Eng Part A (2009) 0.94

Global bidirectional transcription of the Epstein-Barr virus genome during reactivation. J Virol (2013) 0.93

Literature mining on pharmacokinetics numerical data: a feasibility study. J Biomed Inform (2009) 0.93

The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--β1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells. Am J Respir Cell Mol Biol (2010) 0.92

In vivo real-time 3-D intracardiac echo using PMUT arrays. IEEE Trans Ultrason Ferroelectr Freq Control (2014) 0.92

Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos (2008) 0.91

A general linear model for MEG beamformer imaging. Neuroimage (2004) 0.91

Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology (2011) 0.91

Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS One (2012) 0.90

Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90

Sequencing, annotation, and characterization of the influenza ferret infectome. J Virol (2012) 0.89

Versatile roles of V-ATPases accessory subunit Ac45 in osteoclast formation and function. PLoS One (2011) 0.89

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos (2012) 0.89

Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest (2007) 0.89

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol (2012) 0.88

Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos (2002) 0.88

Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol (2005) 0.88

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos (2005) 0.88

Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87

Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures. Gene (2012) 0.87

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol (2002) 0.87

A new probabilistic rule for drug-dug interaction prediction. J Pharmacokinet Pharmacodyn (2009) 0.86

Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution. J Chem Inf Model (2013) 0.86

Autologous tenocyte injection for the treatment of severe, chronic resistant lateral epicondylitis: a pilot study. Am J Sports Med (2013) 0.86

Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways. Biochem Biophys Res Commun (2012) 0.85

Bioreactor design for tendon/ligament engineering. Tissue Eng Part B Rev (2012) 0.85

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos (2005) 0.85

Airflow and droplet spreading around oxygen masks: a simulation model for infection control research. Am J Infect Control (2007) 0.85

Oscillatory beta activity mediates neuroplastic effects of motor cortex stimulation in humans. J Neurosci (2013) 0.85

Insulin sensitivity is preserved despite disrupted endothelial function. Am J Physiol Endocrinol Metab (2006) 0.85

Polybrominated diphenyl ethers in road and farmland soils from an e-waste recycling region in Southern China: concentrations, source profiles, and potential dispersion and deposition. Sci Total Environ (2008) 0.85

Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit (2008) 0.84

[Experimental infection of Sarcocystis suihominis in pig and human volunteer in Guangxi]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2007) 0.84